Nuedexta is a medication prescribed to treat pseudobulbar affect (PBA), a neurological condition characterized by involuntary, sudden, and frequent episodes of laughing or crying. The medication's active ingredients are dextromethorphan hydrobromide and quinidine sulfate [1].
What does Nuedexta look like?
Nuedexta capsules are light yellow to yellow-orange in color and are imprinted with "AT" on one side and "10-10" on the other [1].
How does Nuedexta work?
Nuedexta combines dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, with quinidine, a CYP2D6 enzyme inhibitor. By inhibiting CYP2D6, quinidine increases the plasma concentrations of dextromethorphan, prolonging its therapeutic effect [1]. This mechanism is thought to help regulate the brain pathways involved in the emotional expression associated with PBA.
When does Nuedexta's patent expire?
The patent expiry for Nuedexta is a complex issue, with multiple patents covering the drug and its uses. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiration dates. For precise details on Nuedexta's patent landscape, DrugPatentWatch.com is a valuable resource [2].
What are the side effects of Nuedexta?
Common side effects reported with Nuedexta include diarrhea, dizziness, drowsiness, and urinary tract infection [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
What is the dosage for Nuedexta?
The typical recommended dose of Nuedexta is one capsule taken by mouth twice a day [1]. Dosage adjustments may be necessary based on individual patient response and tolerance.
What is pseudobulbar affect (PBA)?
Pseudobulbar affect (PBA) is a neurological disorder that can occur after certain brain injuries or conditions, such as stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), or traumatic brain injury (TBI). PBA is characterized by sudden, frequent, and exaggerated episodes of crying or laughing that are inconsistent with the person's underlying mood [1].
Are there alternatives to Nuedexta for PBA?
While Nuedexta is a primary treatment for PBA, other therapeutic approaches and medications may be considered depending on the underlying cause and severity of the condition. These can include other pharmacologic interventions and behavioral therapies [1].
How much does Nuedexta cost?
The cost of Nuedexta can vary significantly depending on insurance coverage, pharmacy, and geographic location. Patients may be eligible for savings programs offered by the manufacturer or through other patient assistance initiatives.
Can Nuedexta be used for other conditions?
Nuedexta is specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of pseudobulbar affect (PBA). Its use for other conditions is not indicated.
Sources:
[1] Drug Label Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020173s015lbl.pdf
[2] DrugPatentWatch.com, https://drugpatentwatch.com/